Cybin Corp. appears set for opportunity as new data increasingly finds promise in psychedelic medicines. As big pharma has failed to bring groundbreaking drug innovations into the mental-health space, psilocybin — the main compound of pharmaceutical psychedelic products — stands … Continue reading →

Psychedelics have shown positive results for treatment of mental health conditions including anxiety, depression, PTSD, addiction, eating disorders, ADHD Big pharma failed to bring drug innovations in mental health space; psychedelics may satisfy vast unmet need With secured delivery mechanisms … Continue reading →

Clinical studies show serotonergic psychedelics may be effective in treating anxiety, depression, addiction and more Interest in serotonergic psychedelics has dramatically increased within last decade Cybin Corp. is focused on furthering research, development of psilocybin-based medications through Serenity Life Sciences … Continue reading →

Cybin Corp., a Canada-based, life-sciences company focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market, looks to be in the right place at the right time. A mushrooming interest fuels this sector in an … Continue reading →